- Home
- BHLB vs WVE Comparison
BHLB vs WVE Comparison
Compare BHLB & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BHLB
- WVE
- Stock Information
- Founded
- BHLB 1846
- WVE 2012
- Country
- BHLB United States
- WVE Singapore
- Employees
- BHLB N/A
- WVE N/A
- Industry
- BHLB Banks
- WVE Biotechnology: Pharmaceutical Preparations
- Sector
- BHLB Finance
- WVE Health Care
- Exchange
- BHLB Nasdaq
- WVE Nasdaq
- Market Cap
- BHLB 1.1B
- WVE 915.6M
- IPO Year
- BHLB 2000
- WVE 2015
- Fundamental
- Price
- BHLB $26.32
- WVE $7.82
- Analyst Decision
- BHLB Hold
- WVE Strong Buy
- Analyst Count
- BHLB 5
- WVE 13
- Target Price
- BHLB $32.70
- WVE $20.15
- AVG Volume (30 Days)
- BHLB 516.3K
- WVE 1.2M
- Earning Date
- BHLB 07-24-2025
- WVE 08-07-2025
- Dividend Yield
- BHLB 2.75%
- WVE N/A
- EPS Growth
- BHLB 392.17
- WVE N/A
- EPS
- BHLB 2.46
- WVE N/A
- Revenue
- BHLB $431,403,000.00
- WVE $104,939,000.00
- Revenue This Year
- BHLB $31.27
- WVE N/A
- Revenue Next Year
- BHLB $78.77
- WVE $1.94
- P/E Ratio
- BHLB $10.64
- WVE N/A
- Revenue Growth
- BHLB 33.05
- WVE N/A
- 52 Week Low
- BHLB $22.27
- WVE $5.04
- 52 Week High
- BHLB $32.36
- WVE $16.74
- Technical
- Relative Strength Index (RSI)
- BHLB 58.05
- WVE 67.70
- Support Level
- BHLB $26.28
- WVE $6.25
- Resistance Level
- BHLB $26.96
- WVE $8.13
- Average True Range (ATR)
- BHLB 0.59
- WVE 0.41
- MACD
- BHLB 0.16
- WVE 0.13
- Stochastic Oscillator
- BHLB 76.64
- WVE 92.82
About BHLB Berkshire Hills Bancorp Inc.
Berkshire Hills Bancorp Inc is a holding company. It provides Commercial Banking, Retail Banking, Consumer Lending, Private Banking and Wealth Management services.
About WVE Wave Life Sciences Ltd.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.